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Abstract  
Background A single-centre study of 144 THAs revised specifically for periprosthetic joint 
infection (PJI) observed that trabecular metal (TM) acetabular components had a reduced risk 
of rerevision for subsequent infection compared with non-TM implants. It was suggested that 
TM was protective against infection after revision, and that TM may be useful when revising 
THAs for PJI. Three registry studies have subsequently assessed the effect of TM on future 
infection. In the National Joint Registry (NJR) for England and Wales we earlier reported 
lower revision rates for infection when TM (versus non-TM) was used in primary THA, but 
no difference in re-revision rates for infection when TM was used for all-cause revision 
THAs. The latter findings in all-cause revisions were also confirmed in a study from the 
Swedish and Australian registries. It is possible that TM only reduces the risk of infection 
when it is specifically used for PJI revisions (rather than all-causes). However to date the 
registry analyses have not had large enough cohorts of such cases to assess this meaningfully.  
Questions/purposes (1) In revision THAs performed for PJI, are rerevision rates for all-cause 
acetabular indications lower with TM acetabular components compared with non-TM 
designs? (2) In revision THAs performed for PJI, are rerevision rates of any component for 
infection lower with TM acetabular components compared with non-TM designs? 
Methods A retrospective observational study was performed using NJR data from England 
and Wales, which is the world’s largest arthroplasty registry and contains details of over two 
million joint replacement procedures. The registry achieves high levels of patient consent 
(92%) and linked procedures (ability to link serial procedures performed on the same patient 
and hip; 94%). Furthermore, recent validation studies have demonstrated that when revision 
procedures have been captured within the NJR, the data completion and accuracy were 
excellent. Of 11,988 revisions performed for all causes, 794 were performed for PJI in which 
the same cementless acetabular component produced by one manufacturer was used. 
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Acetabular components were either TM (n = 541) or non-TM (n = 253). At baseline the two 
groups were comparable for sex, age, body mass index, and American Society of 
Anesthesiologists (ASA) grade. Outcomes after revision THA (rerevision for all-cause 
acetabular indications and rerevision of any component for infection) were compared 
between the groups using Fine and Gray regression analysis, which considers the competing 
mortality risk. Regression models were adjusted for the propensity score, with this score 
summarizing many of the potential patient and surgical confounding factors (age, sex, ASA 
grade, surgeon grade, approach, and type of revision procedure performed). 
Results There was no difference in 5-year cumulative acetabular component survival rates 
between TM (96.3%; 95% confidence interval [CI], 94%-98%) and non-TM components 
(94.4%, 95% CI, 90%-97%; subhazard ratio, 0.78, 95% CI, 0.37-1.65; p = 0.509). There was 
no difference in 5-year cumulative implant survival rates free from infection between TM 
(94.8%; 95% CI, 92%-97%) and non-TM components (94.4%, 95% CI, 90%-97%; subhazard 
ratio, 0.97, 95% CI, 0.48-1.96; p = 0.942). 
Conclusions We found no evidence to support the notion that TM acetabular components 
used for PJI revisions reduced the subsequent risk of all-cause rerevision or the risk of 
rerevision for infection compared with non-TM implants from the same manufacturer. We 
therefore advise caution against recent claims that TM components may protect against 
infection. 
Level of Evidence: Level III, therapeutic study.  
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Introduction 
The burden of revision total hip arthroplasty (THA) is increasing annually with periprosthetic 
joint infection (PJI) being one of the most common indications for revision surgery [1, 13]. 
The management of PJI is extremely challenging; the incidence is increasing, it is associated 
with a high risk of morbidity and mortality, and the economic burden is huge [2, 14, 17]. 
Trabecular metal (TM) acetabular components, made from elemental tantalum, have been 
widely used for revision THA over the last decade [1, 13]. A single-centre study of 144 
THAs revised specifically for PJI observed that TM acetabular components had a reduced 
risk of rerevision for subsequent infection compared with non-TM implants [17]. It was 
suggested that TM was protective against infection after revision, and that TM may be useful 
when revising THAs for PJI. Three registry studies have since assessed the effect of TM on 
the risk of subsequent revision for infection [8, 9, 11]. In the National Joint Registry (NJR) 
for England and Wales we earlier reported lower revision rates for infection when TM 
(versus non-TM) was used in 18,200 primary THAs though this was of questionable clinical 
importance [9]. Using the same registry we also earlier reported no difference in re-revision 
rates for infection when TM (versus non-TM) was used for 3,862 all-cause revision THAs 
[11]. Another study of 6,843 all-cause revisions from two large registries (Sweden and 
Australia) similarly showed that the re-revision rate for PJI was not different when TM or 
non-TM components were used at revision THA [8]. 
It is possible that TM only reduces the risk of infection when it is specifically used for PJI 
revisions, rather than for all-cause revisions. However to date the registry analyses have not 
had large enough cohorts of such PJI revision cases to assess this issue in a meaningful way. 
The study from the Swedish and Australian registries was unable to assess this issue because 
the authors felt that the small number of revision THAs performed for PJI (n = 272) 
precluded any useful analysis [8]. Our previous analysis of 247 revision THAs for PJI from 
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the NJR showed no difference in implant survival rates for both aseptic and septic indications 
between TM and non-TM components; however, the analysis was similarly underpowered 
because of the propensity matched analysis approach which was used [11]. Thus, we sought 
to use the world’s largest arthroplasty registry to evaluate the effect of TM when used in 
revision THAs performed for PJI. 
We therefore asked the following: (1) In revision THAs performed for PJI, are rerevision 
rates for all-cause acetabular indications lower with TM acetabular components compared 
with non-TM designs? (2) In revision THAs performed for PJI, are rerevision rates of any 
component for infection lower with TM acetabular components compared with non-TM 
designs? 
Materials and Methods 
A retrospective observational study was performed using data from the NJR for England and 
Wales. The NJR was established in April 2003 to identify poorly performing implants early. 
The registry now contains details of over two million joint replacement procedures. Patients 
provide voluntary consent for their details to be recorded within the NJR. The unique patient 
identifiers allow linkage of primary THAs to any future procedures in which components are 
removed or exchanged. Details regarding patient consent, procedural linkage, and data 
validity in the NJR have been described [10]. The registry achieves high levels of patient 
consent (92%) and linked procedures (ability to link serial procedures performed on the same 
patient and hip; 94%) [13]. Furthermore, validation studies have demonstrated that when 
revision procedures have been captured within the NJR, the data completion and accuracy 
were excellent [15, 16]. Using unique patient identifiers, the NJR data set was linked to the 
Office for National Statistics database, which provides data on all-cause mortality. The study 
protocol was approved by the NJR Research Subcommittee (RSC2016/14). 
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Anonymized patient data were extracted from the NJR for all revision THAs performed 
between April 1, 2003, and July 30, 2015, in which one of four cementless acetabular 
component designs produced by the same manufacturer were implanted (described 
subsequently). The former date represents when the NJR began collecting data, and the latter 
date ensured a minimum 1-year followup for assessing the study endpoints after revision 
THA. A total of 11,988 THAs (10,480 patients) underwent revision surgery for any cause 
which involved the four acetabular components studied. Only revision THAs performed for 
infection were subsequently included in this study, which involved 7% of the eligible cohort 
(794 THAs in 722 patients) (Table 1). Of these THA revisions for infection, 541 hips were 
TM acetabular designs and 253 hips were non-TM designs. The mean followup after revision 
THA was 5.3 years (range, 1.0-13.5 years), which was not different between the TM and 
non-TM groups. 
The study exposure of interest was whether the revision THA acetabular component was TM 
or non-TM. These components were either made of porous tantalum (TM) or titanium with a 
fiber metal coating (non-TM). Two TM implant designs (TM Modular and Continuum) 
and two non-TM implant designs (Trilogy and Trilogy IT) were studied, which are all 
produced by one manufacturer (Zimmer Biomet, Bridgend, UK). The Trilogy and TM 
Modular designs are similar, and the same is true for the Trilogy IT and Continuum designs; 
however the TM Modular designs are elliptical (i.e. a cup labelled with a 56mm diameter cup 
has a true diameter of 58mm). The main difference between these design pairs is that only 
polyethylene liners can be used with the Trilogy and TM Modular designs, whereas either 
polyethylene or ceramic liners can be used with the Trilogy IT and Continuum designs. 
Details regarding the design and manufacture of these components have been described 
previously [11]. 
The two outcomes of interest after revision THA for infection were rerevision surgery of the 
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acetabular component for all causes, and rerevision surgery of any component for infection 
(regardless of whether the acetabular component was removed). The latter therefore included 
isolated femoral head and/or acetabular liner exchanges for infection. The diagnosis of 
infection is recorded by the revision surgeon on standardized data capture forms, which are 
subsequently submitted to the registry as described previously [11]. This diagnosis is based 
on preoperative and intraoperative findings, but does not include any laboratory analysis of 
samples taken during revision surgery.  
The NJR also collects data on other relevant patient and surgical factors, which could be 
potential confounders. These include age, sex, body mass index (BMI), year of surgery, 
American Society of Anesthesiologists (ASA) grade, surgeon grade, surgical approach, 
specific revision indication, number of revision indications, and type of revision performed 
(single-stage or two-stage procedure, femoral stem revision or retention, revision femoral 
head size, bearing surface, and use of bone graft). Adjustments were made for these potential 
confounders in the analysis. 
The patient age at revision was not different between the TM and non-TM groups (mean 68 
versus 69 years; p=0.494) (Table 1). The sex distribution was not different between the TM 
and non-TM groups (49% females (266/541) versus 45% females (113/253); p=0.236). The 
BMI at revision was not different between the TM and non-TM groups (mean 29 versus 28 
kg/m2; p=0.114). The frequency of bilateral THA revisions was not different between the TM 
and non-TM groups (5% (27/541) versus 4% (9/253); p=0.366). The patient ASA grade at 
revision was not different between the TM and non-TM groups (ASA 1: 7% (36/541) versus 
10% (25/253); ASA 2: 58% (311/541) versus 49% (125/253); ASA 3 or above: 36% 
(194/541) versus 41% (103/253); p=0.065). The TM group more frequently had surgery 
performed by a consultant compared with the non-TM group (95% (511/541) versus 89% 
(226/253); p=0.009). The TM group more frequently had surgery performed using a posterior 
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approach compared with the non-TM group (73% (395/541) versus 60% (152/253); 
p<0.001). The TM group more frequently had fewer indications for revision compared with 
the non-TM group (1 indication +/- pain (compared with 2 or more): 84% (455/541) versus 
75% (191/253); p=0.004). The frequency of single-stage revision procedures was not 
different between the TM and non-TM groups (19% (102/541) versus 21% (52/253); 
p=0.573). The frequency of stem revisions and fixation was not different between the TM 
and non-TM groups (stem revised (uncemented): 53% (286/541) versus 45% (113/253); 
(stem revised (cemented): 39% (210/541) versus 46% (117/253); stem not revised: 8% 
(45/541) versus 9% (23/253); p=0.094). The TM group more frequently had larger femoral 
head sizes implanted at revision compared with the non-TM group (28mm or less: 8% 
(45/541) versus 37% (94/253); 32mm: 29% (156/541) versus 44% (112/253); 36mm or 
above: 63% (340/541) versus 19% (47/253); p<0.001). The TM group more frequently had 
ceramic bearing surfaces implanted at revision compared with the non-TM group (metal-on-
polyethylene: 74% (379/541) versus 86% (211/253); ceramic-on-polyethylene: 21% 
(109/541) versus 13% (31/253); ceramic-on-ceramic: 5% (23/541) versus 1% (3/253); 
p<0.001). The frequency of femoral bone graft used at revision was not different between the 
TM and non-TM groups (3% (18/541) versus 6% (16/253); p=0.052). The frequency of 
acetabular bone graft used at revision was not different between the TM and non-TM groups 
(20% (106/541) versus 16% (41/253); p=0.252). 
Statistical Analysis 
Cumulative implant survivorship after revision THA was determined using the Kaplan-Meier 
method with the two endpoints used for implant survival defined previously. Patients that did 
not experience an outcome event and that remained alive were censored on the study end date 
(July 30, 2016). The study endpoints after revision THA were compared between the TM and 
non-TM groups using Fine and Gray regression analysis, which considers the competing 
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mortality risk [3]. This decision was supported by the high risk of mortality during the study, 
especially in the non-TM group (overall 19% (153/794): TM group 13% (73/541) versus non-
TM group 32% (80/253); p<0.001). Proportional subhazard assumptions were assessed and 
satisfied for all regression analyses.  
Adjusted regression models for each study endpoint were assessed in which adjustment was 
made solely for the propensity score. There were a number of potential patient and surgical 
confounding factors, which could have all been adjusted for in the analysis. However, 
adjusting for all of these confounders individually would substantially increase the risk of 
overfitting the regression models, especially given the relatively small number of observed 
outcome events. A propensity score (ranging from 0 to 1) was generated for each revision 
THA using logistic regression with the methods used described in detail previously [11]. The 
propensity score summarizes all the potential patient and surgical confounding factors (all 
covariates listed in Table 1 apart from BMI as a result of this variable frequently having 
missing data) using one single score per revision THA.  
We used Stata (Version 14.2; College Station, TX, USA) for all analyses. Probability values 
< 0.05 and 95% confidence intervals (CIs) were used. 
Results 
We found no difference in the all-cause risk of acetabular rerevision between the TM group 
and the non-TM group following THA revision for PJI. The 5-year cumulative acetabular 
component survivorship was 96.3% (95% CI, 94%-98%) in the TM group compared with 
94.4% (95% CI, 90%-97%) in the non-TM group (subhazard ratio [SHR], 0.49; 95% CI, 
0.18-1.35; p = 0.169) (Table 2). There were 28 of 794 hips (3.5%), which underwent all-
cause acetabular re-revision within the study period. Mean time to all-cause acetabular 
rerevision was 2.1 years (range, 0.04-6.4 years). The most common reasons for these 
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rerevisions were infection (57%; 16/28), aseptic loosening (32%; 9/28), lysis (14%; 4/28), 
and dislocation/subluxation (11%; 3/28).  
We found no difference in the risk of rerevision of any component for infection between the 
TM group and the non-TM group following THA revision for PJI. The 5-year cumulative 
implant survivorship free from infection was 94.8% (95% CI, 92%-97%) in the TM group 
compared with 94.4% (95% CI, 90%-97%) in the non-TM group (SHR, 0.70; 95% CI, 0.29-
1.69; p = 0.427) (Table 2). There were 34 of 794 hips (4.3%), which underwent re-revision 
for infection within the study period. Mean time to rerevision of any component for infection 
was 2.5 years (range, 0.05-7.2 years). 
Discussion 
The burden of revision THA is increasing with PJI being one of the most common indications 
for revision surgery [1, 13]. A single-centre study of 144 THAs revised for PJI observed that 
TM acetabular components had a reduced risk of rerevision for subsequent infection 
compared with non-TM implants [17]. It was suggested that TM was protective against 
infection after revision, and that TM may be useful when revising THAs for PJI. Three 
registry studies have subsequently assessed the effect of TM on future infection [8, 9, 11]. In 
the NJR for England and Wales we earlier reported lower revision rates for infection when 
TM (versus non-TM) was used in primary THA [9], but no difference in re-revision rates for 
infection when TM was used for all-cause revision THAs [11]. The latter findings in all-
cause revisions were also confirmed in a study from the Swedish and Australian registries 
[8]. It is possible that TM only reduces the risk of infection when it is specifically used for 
PJI revisions, rather than revisions for all-causes. However to date the registry analyses have 
not had large enough cohorts of such PJI revision cases to assess this meaningfully. The 
present large nationwide registry study demonstrated that in revision THAs performed for 
PJI, the risk of all-cause acetabular component rerevision and the risk of rerevision of any 
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component for infection were not different in patients receiving TM- and non-TM acetabular 
components. 
This study had a number of limitations. First, our study was subject to selection bias given 
that TM components may have preferentially been chosen over non-TM components for PJI 
revisions for numerous reasons. These potential reasons include patient factors (such as age, 
sex, BMI, comorbidities such as diabetes, and medications such as steroids or 
immunosuppressants) and surgical factors (such as surgeon training and experience with each 
implant, case complexity, and the extent of acetabular defects). We controlled for as many of 
these variables as we reasonably could in the propensity score adjustment (including age, sex, 
ASA grade, the number of revision indications, and bone graft use). However there were a 
number of factors that we could not control for, including medical and drug history, and 
certain aspects of case complexity. It is important to acknowledge that joint registries do not 
record the extent of acetabular defects encountered at revision THA nor do they have 
radiographic records available to retrospectively assess such defects. It has been suggested 
that TM components may be used in more-complex revisions where larger acetabular defects 
are present, which may put them at an increased risk of future rerevision compared with non-
TM components [8, 17]. Along with other potential patient and surgical confounders not 
available in the registry, the lack of acetabular defect data therefore represents an important 
limitation of registry analyses when assessing the outlined research questions and could 
influence the interpretation of our findings. Although our analysis in a large dataset was as 
robust as possible, we would recommend future studies take these factors into account when 
interpreting the data. However, other registry analyses have adjusted for the use of acetabular 
augments, which did not change their findings [8]. Furthermore, we consider that our work 
adds to what is known given the very large number of revision THAs for PJI needed to 
satisfactorily assess our study’s key questions, which will not available in single-center 
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studies. 
Second, registries currently do not collect data on the histopathologic and microbiologic 
analyses performed on tissue and fluid samples taken at revision surgery. Therefore, some of 
the cohort studied may have not truly had PJI after sample analysis and similarly the 
rerevision rates for subsequent infection may be slightly different if these sample analyses 
had been considered. However, this will not have influenced the acetabular rerevision rate for 
all causes. Third, using observational data means, we cannot infer causality. Fourth, previous 
NJR studies have suggested that rerevision rates may be underestimated [15, 16], although 
there is no reason to expect any underreporting would differ between the TM and non-TM 
groups. Fifth, registries do not collect data on nonrevision procedures such as closed 
reductions or wound washouts nor do they collect data on patient-reported outcome measures 
after revision surgery. It is recognized that these endpoints are important when assessing the 
outcomes after any surgical intervention. Sixth, it is acknowledged that the rerevision risk 
may have been artificially low because of the competing mortality risk, given that a number 
of patients died during follow-up thus precluding them from undergoing rerevision. However 
we have mitigated this by performing competing risk regression analyses, which accounted 
for the risk of mortality. Finally, our observations cannot be extrapolated to highly porous 
acetabular component designs produced by other manufacturers. 
After revision THA performed for PJI, TM acetabular components had a risk of all-cause 
rerevision, which was comparable to non-TM components in the present study. The 
perceived advantages of TM acetabular components have led to an increase in their use 
worldwide for both primary and revision THA [8, 9, 11]. A small study of 46 revision THAs 
for all causes in which TM components were used reported a 96% survival rate for the 
acetabular component at 11 years with excellent pain relief and good functional outcomes 
observed in patients with surviving implants [6]. Other authors comparing implant survival 
14 
 
 
after all-cause revision THA performed with TM or non-TM acetabular components have 
reported better implant survival and fewer radiologic failures in the TM group [5, 17]. 
However, similar analyses in all-cause revision THA cohorts from national registries from 
Mohaddes et al. (n = 2460), Kremers et al. (n = 3448), Laaksonen et al. (n = 6843), and 
Matharu et al. (n = 3862) have failed to demonstrate any improvement in all-cause implant 
survival when using TM acetabular components compared with non-TM components [7, 8, 
11, 12]. The present study is the largest analysis of revision THAs performed specifically for 
PJI. Our findings regarding the subsequent risk of acetabular rerevision for all causes are in 
concordance with previous registry data based on revision THAs performed for any 
indication and now therefore question the clinical benefit of TM components in revision 
THAs performed specifically for infection. 
After revision THA performed for PJI, the risk of rerevision of any component for infection 
was comparable between TM- and non-TM acetabular components in the present study. The 
notion that TM components used in THAs revised for PJI may protect against subsequent 
infection comes from a small single-center study involving 144 revision THAs performed for 
PJI [17]. After patients were followed up for a minimum of 90 days from revision (mean of 3 
years), the risk of rerevision resulting from subsequent infection (defined as infection 
recurrence or persistence) was lower in the TM group (3%) compared with the non-TM 
group (18%) [17]. Potential mechanisms proposed by the authors for the reduced risk of 
infection observed with TM implants included the increased potential for osseointegration 
(which may reduce dead space for colonizing organisms), TM being more hostile to 
organisms with lower bacterial adhesion compared with other orthopaedic materials (possibly 
as a result of its three-dimensional structure) and TM enhancing local host defense systems 
by promoting leukocyte activation [4, 17]. However, a recent matched analysis, albeit 
underpowered, of revision THAs performed for PJI from the NJR (n = 247) showed no 
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difference in implant survival rates for septic indications between TM and non-TM 
components [11]. The findings from the present much larger study based on an unselected 
national population with longer followup compared with the study by Tokarski et al. [17] 
(including a minimum of 1 year) also do not support the suggestion that TM components 
used in THAs revised for PJI are protective against subsequent infection. 
This large nationwide registry study demonstrated that after revision THA performed for PJI, 
TM acetabular components had a risk of all-cause rerevision that was comparable with non-
TM components. Contrary to the findings from a recent small study [17], we also found no 
evidence to support the notion that TM acetabular components used for PJI revisions reduced 
the subsequent risk of rerevision for infection compared with non-TM implants from the 
same manufacturer. At this time, we would therefore advise that clinicians exercise caution 
regarding previous claims that TM components may protect against subsequent infection. 
Future work should include testing this contention in other large patient cohorts as well as 
analyzing the data periodically in the medium to long term to establish whether TM 
components can confer any survival benefit over non-TM components at extended followup.  
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Table 1. Patient and surgical factors in the cohort undergoing revision THA performed for 
periprosthetic joint infection 
Covariate All revision THAs  
(n = 794) 
(100%) 
TM cups 
(n = 541) 
(68%) 
Non-TM cups 
(n = 253) 
(32%) 
p-value  
Sex 
Female versus male 
 
379 (48)  
 
266 (49) 
 
113 (45) 
 
0.236 
Age at revision (years), 
mean (SD) 
 
69 (12) 
 
68 (12) 
 
69 (11) 
 
0.494 
BMI (kg/m2),* 
mean (SD) 
 
29 (6) 
 
29 (6) 
 
28 (6) 
 
0.114 
Bilateral revisions 36 (5)  27 (5) 9 (4) 0.366 
Revision ASA grade  
1 
2 
3 or above 
 
61 (8) 
436 (55) 
297 (37) 
 
36 (7) 
311 (58) 
194 (36) 
 
25 (10) 
125 (49) 
103 (41) 
 
0.065 
Surgeon grade, 
consultant versus other 
 
737 (93) 
 
511 (95) 
 
226 (89) 
 
0.009 
Surgical approach, 
posterior versus other 
 
547 (69) 
 
395 (73) 
 
152 (60) 
 
<0.001 
Number of indications, 1 
( pain) versus 2 or more 
 
646 (81) 
 
455 (84) 
 
191 (75) 
 
0.004 
Revision procedure, 
single-stage versus two-
stage 
 
154 (19) 
 
102 (19) 
 
52 (21) 
 
0.573 
Revision performed 
Stem revised 
(uncemented) 
Stem revised  
(cemented) 
Stem not revised 
 
399 (50) 
 
327 (41) 
 
68 (9) 
 
286 (53) 
 
210 (39) 
 
45 (8) 
 
113 (45) 
 
117 (46) 
 
23 (9) 
 
0.094 
Femoral head size (mm) 
28 or less 
32  
36 or above 
 
139 (18) 
268 (34) 
387 (49) 
 
45 (8) 
156 (29) 
340 (63) 
 
94 (37) 
112 (44) 
47 (19) 
 
<0.001 
Bearing surface 
MoP  
CoP 
CoC 
N/A 
 
590 (78) 
140 (19) 
26 (3) 
38 
 
379 (74) 
109 (21) 
23 (5) 
30 
 
211 (86) 
31 (13) 
3 (1) 
8 
 
<0.001 
     
Bone graft  
(femoral) 
 
34 (4) 
 
18 (3) 
 
16 (6) 
 
0.052 
Bone graft  
(acetabular) 
 
147 (19) 
 
106 (20) 
 
41 (16)  
 
0.252 
*Missing data for stated number of hips: BMI (n = 435); values in parentheses are 
percentages unless otherwise indicated; TM = trabecular metal; BMI = body mass index; 
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ASA = American Society of Anesthesiologists; MoP = metal-on-polyethylene; CoP = 
ceramic-on-polyethylene; CoC = ceramic-on-ceramic; N/A = not available; SD = standard 
deviation. 
When comparing covariates between the TM and non-TM groups, numerical data were 
compared using unpaired t-tests, and categorical data were compared using either the Chi-
squared test or Fisher’s exact test (latter used if less than five observations in any group). P-
values less than 0.05 are highlighted in bold text. 
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Table 2. Implant survival after revision THA performed for periprosthetic joint infection 
when using trabecular metal and nontrabecular metal acetabular components 
Revisions for periprosthetic 
joint infection 
Number 
of hips 
(%) 
 
5-year acetabular 
component survival 
rate 
(95% CI) 
 
5-year implant 
survival rate free 
from infection  
(95% CI) 
 
Overall 794 
(100) 
 
95.7% 
(94%-97%) 
94.7% 
(93%-96%) 
TM cup 541 
(68) 
 
96.3% 
(94%-98%) 
94.8% 
(92%-97%) 
Non-TM cup 253  
(32) 
 
94.4% 
(90%-97%) 
94.4% 
(90%-97%) 
SHR (95% CI) 
adjusted for the propensity 
score 
 0.49 
(0.18-1.35) 
p = 0.169 
 
0.70 
(0.29-1.69) 
p = 0.427 
Hazard ratio for Cox 
regression (95% CI) 
adjusted for the propensity 
score 
 0.49 
(0.19-1.28) 
p = 0.144 
0.70 
(0.28-1.74) 
p = 0.437 
Subhazard ratios < 1 represent a reduced risk of the specified outcome in TM cups; CI = 
confidence interval; TM = trabecular metal; SHR = subhazard ratio; ASA = American 
Society of Anesthesiologists. 
 
 
